טוען...

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

Hepatic steatosis is frequently observed in obese and aged individuals. Because hepatic steatosis is closely associated with metabolic syndromes, including insulin resistance, dyslipidemia, and inflammation, numerous efforts have been made to develop compounds that ameliorate it. Here, a novel perox...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Kim, Seong Min, Lee, Bonggi, An, Hye Jin, Kim, Dae Hyun, Park, Kyung Chul, Noh, Sang-Gyun, Chung, Ki Wung, Lee, Eun Kyeong, Kim, Kyung Mok, Kim, Do Hyun, Kim, Su Jeong, Chun, Pusoon, Lee, Ho Jeong, Moon, Hyung Ryong, Chung, Hae Young
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542266/
https://ncbi.nlm.nih.gov/pubmed/28545035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17695
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!